Equity Overview
Price & Market Data
Price: $0.96
Daily Change: +$0.02 / 2.08%
Range: $0.932 - $0.99
Market Cap: $22,895,904
Volume: 41,544
Performance Metrics
1 Week: 2.10%
1 Month: -5.88%
3 Months: -17.24%
6 Months: -21.31%
1 Year: -30.43%
YTD: -17.95%
Company Details
Employees: 36
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.